secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2026-11-10T21:55:25+00:00
Accession:  0001193125-26-455669
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Acrivon introduces ACR-525 and PKCθ inhibitor preclinical I&I programs targeting EoE
--------------------------------------------------------------------------------

- Nov 10, 2026 R&D webcast introduced ACR-525 and a PKCθ inhibitor, both preclinical, with initial development plans in eosinophilic esophagitis (EoE).
- Dr. Arjan Bredenoord (Amsterdam UMC), EoE principal investigator, covered epidemiology and unmet need; Dr. Evan Dellon (UNC) reviewed EoE standard of care.
- Programs were identified with Acrivon's AI-driven AP3 platform and mark the company's entry into immunology and inflammation.
- No preclinical data, IND timing, trial endpoints or financial terms were disclosed; the posted exhibit is only a title slide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526455669/0001193125-26-455669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526455669/acrv-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer